{"schema_version":"1.0","type":"article","title":"A new US therapy for muscle-wasting disease: bringing four-weekly infusions into everyday care","url":"https://drugnews.com.tw/articles/2026-09-26-scholar-rock-isembyld-sma-care-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-26-scholar-rock-isembyld-sma-care-en.md","lang":"en","date":"2026-09-26","publish_at":"2026-09-26T08:00:00+08:00","updated_at":"2026-09-26","category":"商業分析系列","topic":"商業分析系列","tags":["SMA","Scholar Rock","ISEMBYLD","Muscle-directed therapy","AnnJi"],"summary":"US approval of ISEMBYLD adds a muscle-directed option for people with SMA receiving SMN2-targeting therapy. This analysis connects functional trial gains and safety follow-up with payment, four-weekly infusions and continued care, while distinguishing AnnJi's adjacent Taiwanese neuromuscular drug-development program from SMA or a proven commercial partnership.","key_points":[],"facts":[],"sections":["【01｜Targeting Muscle to Build Value Beyond Existing Treatment】","【02｜How the 2.2-Point Difference Was Produced Shapes the Efficacy Story】","【03｜Eligible Patients and Safety Define the Boundaries of Long-Term Value】","【04｜About 6,600 Is a Company Estimate of the Patient Population—Starting Treatment Is Another Step】","【05｜Infusions Every Four Weeks Make Continued Treatment Another Commercial Test】","【06｜Taiwan's Relevant Capability: Moving a Drug Candidate Into Human Evaluation】","【Conclusion｜Value After Launch Comes From Moving Trial Gains Into Everyday Treatment】","【Sources】"],"references":[],"images":[{"alt":"A muscle-directed treatment option is shown alongside patient assessment, payment documents and an infusion-care setting, connecting the new therapy with the practical steps needed for everyday use.","url":"https://drugnews.com.tw/assets/articles/scholar-rock-isembyld-sma-care-en/01_%E6%96%B0%E5%A2%9E%E7%99%82%E6%B3%95%E8%88%87%E6%97%A5%E5%B8%B8%E4%BD%BF%E7%94%A8_EN_v2.png"},{"alt":"A motor neuron connects to a muscle fiber, with separate labels for SMN2 background treatment and muscle-directed ISEMBYLD. An inset depicts inhibition of myostatin activation without showing nerve regeneration or restoration to normal function.","url":"https://drugnews.com.tw/assets/articles/scholar-rock-isembyld-sma-care-en/02_%E7%A5%9E%E7%B6%93%E5%85%83%E8%88%87%E8%82%8C%E8%82%89_EN_v1.png"},{"alt":"Two bars share a common zero baseline: ISEMBYLD 10 mg/kg plus background treatment shows a +1.0-point change, and placebo plus background treatment shows a −1.2-point change. A bracket marks the 2.2-point difference, with the 52-week time point, age and ambulatory-status criteria, and group sizes of 53 and 50.","url":"https://drugnews.com.tw/assets/articles/scholar-rock-isembyld-sma-care-en/03_%E5%85%A9%E7%B5%84%E5%8A%9F%E8%83%BD%E5%B7%AE%E7%95%B0_EN_v2.png"},{"alt":"A patient and caregiver are surrounded by three equally weighted areas: functional assessments, safety follow-up records, and an infusion calendar with payment documents. The calendar indicates treatment every four weeks; no guaranteed continuation, cure or revenue growth is shown.","url":"https://drugnews.com.tw/assets/articles/scholar-rock-isembyld-sma-care-en/04_%E6%8C%81%E7%BA%8C%E6%B2%BB%E7%99%82%E4%B8%89%E9%9D%A2%E5%90%91_EN_v2.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/scholar-rock-isembyld-sma-care-en/01_%E6%96%B0%E5%A2%9E%E7%99%82%E6%B3%95%E8%88%87%E6%97%A5%E5%B8%B8%E4%BD%BF%E7%94%A8_EN_v2.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-26）。A new US therapy for muscle-wasting disease: bringing four-weekly infusions into everyday care。https://drugnews.com.tw/articles/2026-09-26-scholar-rock-isembyld-sma-care-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-09-26-scholar-rock-isembyld-sma-care.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}